2855 GAZELLE COURT, CARLSBAD, CA
Announces Positive Interim Data from Partner Roche’s Phase 3 IMAgINATION Study in IgA Nephropathy (IgAN)
Announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
ZANVASTRO Approved by the FDA as the First and Only Disease Modifying Treatment for Alexander Disease (AxD) in Pediatric and Adult Patients
Financial Results, Press Release
News
Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy
Proven to deliver significant and robust triglyceride reductions –– Only treatment for sHTG indicated to reduce the risk of acute pancreatitis –– first independent commercial launch in a prevalent condition –– to host webcast today at 3:30 p.m. ET
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Amended Notice of Proposed Sale of Securities